The Jab: Why can’t more be made?
Thousands are dying each day amid vaccine shortages. Would a patent waiver save lives?Jayati Ghosh of the University of Massachusetts Amherst says liberating IP is an urgent moral issue. Richard Hatchett, CEO at CEPI, disagrees.Alok Jha and Natasha Loder are joined by Edward Carr, our deputy editor, and economics columnist Ryan Avent.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts See acast.com/privacy for privacy and opt-out information.